Skip to content

Study · Case report or series · n = 3 · 2024

4 results

Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review.

Koceva A, Mlekuš Kozamernik K, Janež A, Herman R, Ferjan S, Jensterle M

Frontiers in endocrinology21 Jan 2025Cited by 3 (Europe PMC)

PMID39906041 (opens in a new tab)PMCIDPMC11790462 (opens in a new tab)DOI10.3389/fendo.2024.1528457 (opens in a new tab)PepBankPUB-39906041
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

IntroductionPrader-Willi syndrome (PWS) is the most prevalent cause of syndromic obesity. Obesity development in PWS is driven by dysfunction in neural pathways involved in satiety and reward, dysregulation in hormones regulating satiety and food intake, altered body composition and reduced energy expenditure, as well as the presence of various hormone deficiencies. As hyperphagia, satiety dysfunction and consequent food-seeking behaviors are intrinsic to PWS, obesity management can be challenging.Case seriesWe present a long-term follow-up of treatment with GLP-1 receptor agonist (GLP-1 RA) semaglutide in three patients with PWS without diabetes, one of whom had previously undergone metabolic surgery. Semaglutide treatment at dosages from 0.5 mg to 2 mg weekly demonstrated variable efficacy, from preventing further weight gain in patient 1, to achieving weight loss of up to 14.4% and 11% relative to baseline, in Patient 2 and Patient 3. It was well tolerated, even after metabolic surgery.ConclusionLong-term randomized placebo-controlled trials with larger sample sizes are needed to provide stronger evidence on the long-term efficacy and safety of semaglutide for obesity treatment in PWS as well as explore the potential synergistic effects of GLP-1 RA treatment combined with other therapeutic interventions.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In three patients with Prader-Willi syndrome, semaglutide was well tolerated, including after metabolic surgery.

    In plain wordsIn three people with Prader-Willi syndrome, semaglutide was well tolerated, even after metabolic surgery.

    Peptide
    Semaglutide
    Outcome
    Not applicableTolerability
    Study

    n = 3

    Outcome group
    Adverse events · Whole body
    Studied dose
    0.5 mg to 2 mg weeklyAs given in this study (human).

    Source sentences

    Summary
    It was well tolerated, even after metabolic surgery.
    1 context sentence
    Summary · context
    We present a long-term follow-up of treatment with GLP-1 receptor agonist (GLP-1 RA) semaglutide in three patients with PWS without diabetes, one of whom had previously undergone metabolic surgery.
  2. 02HumanCase report or seriesEfficacy outcome

    In a patient with Prader-Willi syndrome and no diabetes, long-term semaglutide prevented further weight gain.

    In plain wordsIn one person with Prader-Willi syndrome, semaglutide stopped further weight gain.

    Peptide
    Semaglutide
    Outcome
    No significant changeWeight change in patient 1
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.5 mg to 2 mg weeklyAs given in this study (human).

    Source sentences

    Summary
    Semaglutide treatment at dosages from 0.5 mg to 2 mg weekly demonstrated variable efficacy, from preventing further weight gain in patient 1
    1 context sentence
    Summary · context
    We present a long-term follow-up of treatment with GLP-1 receptor agonist (GLP-1 RA) semaglutide in three patients with PWS without diabetes, one of whom had previously undergone metabolic surgery.
  3. 03HumanCase report or seriesEfficacy outcome

    In a patient with Prader-Willi syndrome, semaglutide led to weight loss of up to 14.4% relative to baseline.

    In plain wordsIn one person with Prader-Willi syndrome, semaglutide led to weight loss of up to 14.4% from baseline.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss in patient 2
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.5 mg to 2 mg weeklyAs given in this study (human).

    Measurements

    Weight loss
    ≤ 14.4%
    patient 2

    Source sentences

    Summary
    achieving weight loss of up to 14.4% and 11% relative to baseline, in Patient 2 and Patient 3
    1 context sentence
    Summary · context
    We present a long-term follow-up of treatment with GLP-1 receptor agonist (GLP-1 RA) semaglutide in three patients with PWS without diabetes, one of whom had previously undergone metabolic surgery.
  4. 04HumanCase report or seriesEfficacy outcome

    In a patient with Prader-Willi syndrome, semaglutide led to weight loss of 11% relative to baseline.

    In plain wordsIn one person with Prader-Willi syndrome, semaglutide led to 11% weight loss from baseline.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss in patient 3
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.5 mg to 2 mg weeklyAs given in this study (human).

    Measurements

    Weight loss
    11%
    patient 3

    Source sentences

    Summary
    achieving weight loss of up to 14.4% and 11% relative to baseline, in Patient 2 and Patient 3
    1 context sentence
    Summary · context
    We present a long-term follow-up of treatment with GLP-1 receptor agonist (GLP-1 RA) semaglutide in three patients with PWS without diabetes, one of whom had previously undergone metabolic surgery.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.